HOF Therapeutics
.png)
Mission
Our Cell Assembly Programming (CAP) is ideal for cell therapy in patients because its most important steps precede implantation in humans, thereby preparing cells to form complex structures. None of the hundreds of clinical stem cell trials conducted to date have used CAP technology and the success rate for implanting cells in solid tissues is currently zero. Yes, there is the rare patient who responds positively, but none of the trials have shown high reproducibility of a solid tissue cell therapy, thus there are no FDA approved solid tissue therapies. Trials yielding negative results are put on hold rather than admitting failures. There is a saying, 'repeating the same actions over and over and expecting a different result is the definition of insanity'. It is time to stop the insanity and put CAP to work in multiple clinical trials!
Vision
We share a vision of extending the quality of human life by enabling regeneration of the human body. This will be the new medicine for the next century. We are happy to have a shared vision with others, and are convinced that the efforts of many people will help bring this to fruition. It is time to greatly accelerate our efforts to bring effective cell therapies to patients.
Join us in asking the FDA to require preclinical data for cell therapies; where the cell population to be administered to patients has been tested for its ability to reform multicellular structures in lab tissue culture without further addition of any matrices or growth factors, since these cannot be added to patients. Only if it forms in the lab will it also form in patients.
* HOF Therapeutics can be contracted to provide your company with the FDA required preclinical data for an IND using cells of your choice and our CAP method. Please contact us.